All In Biotech

Drug Trial Radar · NCT04963231

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

A 2-Stage (Open-Label Followed by Randomized Double-Blind, Placebo-Controlled Stage), Phase 2 Trial of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

164

Actual

Start

Nov 30, 2021

Primary completion

Aug 4, 2023

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.

Conditions

  • Genetic Obesity

Interventions

  • SetmelanotideDrug

    SC injection

  • PlaceboDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1Time frame: Baseline to Week 16

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • HonorHealth Bariatric Center

    Scottsdale, Arizona

  • InQuest Medical Reseacrh

    Suwanee, Georgia

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Metro Detroit Endocrinology Center

    Dearborn, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Ten's Medical Center - Pediatric Endocrinology Clinic

    Staten Island, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Geisinger Clinic

    Danville, Pennsylvania

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Tech

    Amarillo, Texas

  • Endocrine Associates of Dallas and Plano

    Dallas, Texas

  • Hector Granados PA

    El Paso, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Accurate Clinical Research

    Houston, Texas

  • Rio Grande Valley Endocrine Center

    McAllen, Texas

  • Clinical Trials of Texas

    San Antonio, Texas

  • Javara Research

    The Woodlands, Texas

  • University of Alberta

    Edmonton, Alberta, Canada

  • Charite - Universitatsmedizin Berlin

    Berlin, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, Germany

  • Universitaetsklinikum Ulm

    Ulm, Germany

  • University of Patras School of Medicine

    Pátrai, Greece

  • Chaim Sheba MC, Safra Children's Hospital

    Ramat Gan, Israel

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Hospital Infantil Universitario Nino Jesus

    Madrid, Spain

  • Hospital Fundación Jimenez Díaz

    Madrid, Spain

  • Hospital General de Valencia

    Valencia, Spain

  • Bristol Royal Hospital for Children

    Bristol, United Kingdom

  • University of Cambridge

    Cambridge, United Kingdom

  • London Medical - The London Diabetes Centre

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.